The contribution of arterio-venous extracorporeal lung assist to gas exchange in a porcine model of lavage-induced acute lung injury

Hepatic effects of lung-protective pressure-controlled ventilation and a combination of high-frequency oscillatory ventilation and extracorporeal lung assist in experimental lung injury

Background

Ventilation with high positive end-expiratory pressure (PEEP) can lead to hepatic dysfunction. The aim of this study was to investigate the hepatic effects of strategies using high airway pressures either in pressure-controlled ventilation (PCV) or in high-frequency oscillatory ventilation (HFOV) combined with an arteriovenous extracorporeal lung assist (ECLA).

Material/Methods

Pietrain pigs underwent induction of lung injury by saline lavage. Ventilation was continued for 24 hours either as PCV with tidal volumes of 6 ml/kg and PEEP 3 cmH₂O above the lower inflection point of the pressure-volume curve or as HFOV (≥12 Hz) with a mean tracheal airway pressure 3 cmH₂O above the lower inflection point combined with arteriovenous ECLA (HFOV+ECLA). Fluids and norepinephrine stabilized the circulation. The indocyanine green plasma disappearance rate, serum bilirubin, aspartate aminotransferase, alanine aminotransferase, γ-glutamyltransferase, alkaline phosphatase, glutamate dehydrogenase, lactate dehydrogenase and creatine kinase were determined repeatedly. Finally, liver neutrophils were counted and liver cell apoptosis was assessed by terminal deoxynucleotidyl transferase nick end labeling (TUNEL).

Results

Aspartate aminotransferase increased in the PCV group about three-fold and in the HFOV+ECLA group five-fold (p<0.001). Correspondingly, creatine kinase increased about two-fold and four-fold, respectively (p<0.001). Lactate dehydrogenase was increased in the HFOV+ECLA group (p<0.028). The number of neutrophils infiltrating the liver tissue and the apoptotic index were low.

Conclusions

High airway pressure PCV and HFOV with ECLA in the treatment of lavage-induced lung injury in pigs did not cause liver dysfunction or damage. The detected elevation of enzymes might be of extrahepatic origin.

Non-toxic alveolar oxygen concentration without hypoxemia during apnoeic oxygenation: an experimental study

BACKGROUND

Oxygenation without tidal breathing, i.e. apnoeic oxygenation in combination with extracorporeal carbon dioxide removal, might be an option in the treatment of acute respiratory failure. However, ventilation with 100% O₂, which is potentially toxic, is considered a prerequisite to ensure acceptable oxygenation. We hypothesized that trapping nitrogen (N₂) in the lungs before the start of apnoeic oxygenation would keep the alveolar O₂ at a non-toxic level and still maintain normoxaemia. The aim was to test whether a predicted N₂ concentration would agree with a measured concentration at the end of an apnoeic period.

METHODS

Seven anaesthetized, muscle relaxed, endotracheally intubated pigs (22-27 kg) were ventilated in a randomized order with an inspired fraction of O₂ 0.6 and 0.8 at two positive end-expiratory pressure levels (5 cm and 10 cm H₂O) before being connected to continuous positive airway pressure using 100% O₂ for apnoeic oxygenation. N₂ was measured before the start of and at the end of the 10-min apnoeic period. The predicted N₂ concentration was calculated from the initial N₂ concentration, the end-expiratory lung volume, and the anatomical dead space.

RESULTS

The mean difference and standard deviation between measured and predicted N₂ concentration was -0.5 ± 2%, P = 0.587. No significant difference in the agreement between measured and predicted N₂ concentrations was seen in the four settings.

CONCLUSIONS

This study indicates that it is possible to predict and keep alveolar N₂ concentration at a desired level and, thus, alveolar O₂ concentration at a non-toxic level during apnoeic oxygenation.

Arteriovenous Extracorporeal Lung Assist Allows For Maximization Of Oscillatory Frequencies: A Large-animal Model Of Respiratory Distress

Background

Although the minimization of the applied tidal volume (VT) during high-frequency oscillatory ventilation (HFOV) reduces the risk of alveolar shear stress, it can also result in insufficient CO₂-elimination with severe respiratory acidosis. We hypothesized that in a model of acute respiratory distress (ARDS) the application of high oscillatory frequencies requires the combination of HFOV with arteriovenous extracorporeal lung assist (av-ECLA) in order to maintain or reestablish normocapnia.

Methods

After induction of ARDS in eight female pigs (56.5 ± 4.4 kg), a recruitment manoeuvre was performed and intratracheal mean airway pressure (mPaw) was adjusted 3 cmH₂O above the lower inflection point (Plow) of the pressure-volume curve. All animals were ventilated with oscillatory frequencies ranging from 3–15 Hz. The pressure amplitude was fixed at 60 cmH₂O. At each frequency gas exchange and hemodynamic measurements were obtained with a clamped and de-clamped av-ECLA. Whenever the av-ECLA was de-clamped, the oxygen sweep gas flow through the membrane lung was adjusted aiming at normocapnia.

Results

Lung recruitment and adjustment of the mPaw above Plow resulted in a significant improvement of oxygenation (p < 0.05). Compared to lung injury, oxygenation remained significantly improved with rising frequencies (p < 0.05). Normocapnia during HFOV was only maintained with the addition of av-ECLA during frequencies of 9 Hz and above.

Conclusion

In this animal model of ARDS, maximization of oscillatory frequencies with subsequent minimization of VT leads to hypercapnia that can only be reversed by adding av-ECLA. When combined with a recruitment strategy, these high frequencies do not impair oxygenation

Clinical experience with the iLA Membrane Ventilator pumpless extracorporeal lung-assist device

Extracorporeal gas exchange by extracorporeal membrane oxygenation has been established clinically in patients with acute lung failure. The interventional lung-assist (iLA) Membrane Ventilator device (Novalung) is a sophisticated representative of a new generation of pumpless extracorporeal lung-assist devices that are driven by the patient's cardiac output and therefore, do not require extracorporeal pump assistance. The system is characterized by a new membrane gas exchange system with optimized blood flow that is integrated in an arteriovenous bypass established by vascular cannulation. This particular pumpless extracorporeal lung-assist device was applied in 1800 patients for artificial lung assistance with easy use and low cost. This article reviews the present state of clinical Novalung device implementation focusing on encountered limitations and conceivable future developments in the field.